Form 4: Cue Biopharma: Executive Receives Stock Grants

Michael Meluzio, VP, Principal Accounting Officer at Cue Biopharma, Inc., was granted restricted and performance stock units.

Summary

• Michael Meluzio, VP, Principal Accounting Officer of Cue Biopharma, Inc., received a grant of 40,942 shares of common stock on July 9, 2026.
• This grant includes restricted stock units (RSUs) that vest over 48 months in equal quarterly installments, contingent on continued service.
• The grant also includes performance stock units (PSUs) with stock-price based vesting conditions tied to achieving closing prices of $33.00, $38.50, and $44.00 for five consecutive trading days.
• If these stock price targets are not met within 24 months of the grant date, the PSUs will be forfeited.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it details standard executive compensation grants rather than significant financial performance or strategic shifts.

Positives

• Grant of equity awards (RSUs and PSUs) to a key executive, indicating potential alignment of executive interests with shareholder value.
• The RSUs provide a steady vesting schedule over 48 months, encouraging long-term commitment.
• The PSUs offer potential upside for the executive if specific stock price targets are met, incentivizing performance.

Negatives

• The PSUs are subject to forfeiture if stock price targets are not met within 24 months, indicating a performance hurdle that may not be achieved.
• The vesting of RSUs is contingent on continued service, meaning any departure before vesting would result in forfeiture of unvested awards.

Risks

• Failure to achieve the specified stock price targets ($33.00, $38.50, $44.00) within 24 months will result in the forfeiture of performance stock units.
• The reporting person's continued service is a condition for vesting of restricted stock units, implying a risk of forfeiture if employment is terminated.

Future Outlook

The future outlook for the performance stock units is dependent on the company's stock price achieving specific targets of $33.00, $38.50, and $44.00 within 24 months from the grant date.

Industry Context

StockSavvy.ai notes that the issuance of performance-based and time-based equity awards to key executives is a common practice in the biopharmaceutical industry to attract, retain, and incentivize talent, especially in companies focused on long-term drug development and market approval.

Stakeholder Impact

• Shareholders: The grants align executive interests with shareholder value creation, potentially leading to improved company performance if stock price targets are met.
• Employees: The continued service requirement for vesting may influence employee retention decisions.
• Management: The executive is incentivized to drive company performance to meet vesting conditions.

Next Steps

• Vesting of restricted stock units over 48 months in equal quarterly installments.
• Achievement of stock-price based vesting conditions for performance stock units within 24 months.

Key Dates

Keywords

Cue Biopharma, Form 4, Stock Grant, RSU, PSU, Executive Compensation, Insider Trading, SEC Filing, Equity Awards, Vesting Schedule